First FDA-approved off-the-shelf MSC therapy turns Mesoblast into a commercial biotech—now the upside hinges on executing two blockbuster Phase 3 shots on goal without CMC or dilution missteps.
Overview
Mesoblast Limited has reached a major commercialization inflection after years as a development-stage cell therapy company. In December 2024, the FDA approved Ryoncil® (remestemcel‑L), the first mesenchymal stromal cell (MSC) therapy approved for any indication in the U.S. and the only approved treatment for children under 12 with steroid-refractory acute graft-versus-host disease (SR‑aGvHD). Ryoncil® became commercially available March 28, 2025 and is now the company’s primary revenue engine, generating US$49m of net revenue in H1 FY26; management guided to US$110–120m for FY26, signaling rapid market penetration. The commercial rollout is structurally advantaged because demand is concentrated in pediatric bone marrow transplant centers: onboarding the top 64 U.S. centers captures ~94% of pediatric BMT procedures, enabling efficient commercialization with relatively modest selling costs. Ryoncil® is positioned as a standardized, off-the-shelf therapy that can be administered immediately in life-threatening inflammatory settings where steroids fail, and real-world experience cited indicates ~84% survival after a 28-day course. Financially, early commercialization shows strong unit economics (reported ~93% gross margin) but the company remains loss-making as it funds late-stage pipeline work. The medium-term equity story is now defined by whether Mesoblast can parlay its validated platform into larger “blockbuster” indications—adult SR‑aGvHD, chronic low back pain (rexlemestrocel‑L), and heart failure (Revascor®)—while maintaining CMC compliance and managing dilution risk.